Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.
about
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological targetHydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodelingAntihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia.Potential interactions of prescription and over-the-counter medications having antioxidant capabilities with radiation and chemotherapy.Combined aliskiren and L-arginine treatment has antihypertensive effects and prevents vascular endothelial dysfunction in a model of renovascular hypertension.Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension.Consistent antioxidant and antihypertensive effects of oral sodium nitrite in DOCA-salt hypertension.Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertensionElevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer.DNA damage and augmented oxidative stress in bone marrow mononuclear cells from Angiotensin-dependent hypertensive mice.Renovascular hypertension leads to DNA damage and apoptosis in bone marrow cells.Matrix metalloproteinases: drug targets for myocardial infarction.Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension.Matrix metalloproteinases are involved in cardiovascular diseases.Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction.Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension.Combined antihypertensive and cardioprotective effects of nebivolol and hydrochlorothiazide in spontaneous hypertensive rats.Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR.Matrix metalloproteinases: a target in in-stent restenosis?.Antihypertensive and antioxidant effects of a single daily dose of sodium nitrite in a model of renovascular hypertension.Beneficial effects of nebivolol and hydrochlorothiazide combination in spontaneously hypertensive rats.Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.Low nitric oxide bioavailability is associated with better responses to sildenafil in patients with erectile dysfunction.Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.
P2860
Q26864722-CA909376-63B7-4137-97A7-E62C0CE1EFABQ30275124-87A77CD3-40E8-47CF-AA1C-2B4BF6A7BB4CQ33775560-EBAD6C41-0D37-455B-BF13-4B213456739FQ34154805-C4040025-7F2D-4C1F-9F2D-DCF12EE64BF8Q34438605-05D76B07-2010-42A1-B170-F6E1B71321A1Q34886548-EE65DAB1-6396-4930-A86B-B52573A4329BQ35216484-528E6F5B-E73F-4033-AE1D-43D619AE85E9Q35818344-4E35F479-357B-4CC8-AAB7-81138EDED1E7Q36042695-C0EF9CCC-AC52-4381-9CB4-4E2CE3419B87Q36640681-38A8DA16-ED07-4A08-8479-9E5230EA7FAFQ36651392-5B341094-809C-496E-94E6-B17BA5B8B2D0Q37052097-15FCEDF9-973E-466F-9629-96296A3BC70EQ37308645-4A56EE33-68D9-4B7C-9CF9-995E2D678BD0Q37393748-E69E1665-3C9D-43E2-B45D-49527314F42EQ38224193-2863CF3B-64DC-4351-B979-D083E00EEFCDQ39143837-99B5532A-208E-4289-958B-93645F016E00Q39255610-2DC5D6A3-EEAE-4D0F-9BCD-C3E888160CABQ39690743-99DC4310-9C34-447D-8CFE-D91E38E6D16BQ43538572-4360B465-8698-44FF-9078-87BEABE04ADFQ44513191-C38FB5B1-A52F-427C-99C3-3235190F86FCQ44784670-8E6EF8D2-B628-49D3-9D4D-9C6625903322Q46601485-30E1467E-925C-4F37-87D2-A0349D42A8C6Q48161084-B3984D2A-EC37-4C5C-823E-37EFC04DDE37Q50982493-D9ECA4D2-475F-447A-B728-A373D0379C3FQ54030546-64DC2E29-A880-44E1-93F0-75A49263FA59
P2860
Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Spironolactone and hydrochloro ...... of renovascular hypertension.
@ast
Spironolactone and hydrochloro ...... of renovascular hypertension.
@en
type
label
Spironolactone and hydrochloro ...... of renovascular hypertension.
@ast
Spironolactone and hydrochloro ...... of renovascular hypertension.
@en
prefLabel
Spironolactone and hydrochloro ...... of renovascular hypertension.
@ast
Spironolactone and hydrochloro ...... of renovascular hypertension.
@en
P2093
P2860
P50
P1476
Spironolactone and hydrochloro ...... l of renovascular hypertension
@en
P2093
J E Tanus-Santos
M C O Salgado
M M Castro
R F Gerlach
P2860
P356
10.1111/J.1476-5381.2010.00678.X
P407
P577
2010-03-19T00:00:00Z